Loading...
PDEX logo

Pro-Dex, Inc.NasdaqCM:PDEX Rapport sur les actions

Capitalisation boursière US$194.1m
Prix de l'action
US$63.47
US$70
9.3% sous-évalué décote intrinsèque
1Y43.0%
7D10.5%
Valeur du portefeuille
​
Voir

Pro-Dex, Inc.

NasdaqCM:PDEX Rapport sur les actions

Capitalisation boursière : US$194.1m

Pro-Dex (PDEX) Aperçu de l'action

Pro-Dex, Inc. conçoit, développe, fabrique et vend des instruments chirurgicaux motorisés pour les fabricants d'équipements médicaux dans le monde entier. Plus de détails

PDEX analyse fondamentale
Score flocon de neige
Évaluation2/6
Croissance future0/6
Performances passées5/6
Santé financière6/6
Dividendes0/6

Récompenses

Le ratio cours/bénéfice ( 16.9 x) est inférieur au marché US ( 18.5 x)

Les bénéfices ont augmenté de 28.1% au cours de l'année écoulée

Analyse des risques

Les bénéfices devraient diminuer en moyenne de 20.3% par an au cours des 3 prochaines années

Des éléments non récurrents importants ayant un impact sur les résultats financiers


PDEX Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Pro-Dex, Inc. Concurrents

Historique des prix et performances

Résumé des hausses, des baisses et des variations du cours de l'action pour la période du 1er janvier au 31 décembre 2009 Pro-Dex
Historique des cours de bourse
Prix actuel de l'actionUS$63.47
Plus haut sur 52 semainesUS$63.92
Plus bas sur 52 semainesUS$23.47
Bêta-0.11
Variation sur 1 mois19.08%
Variation sur 3 mois62.74%
Variation sur 1 an42.95%
Variation sur 3 ans242.71%
Variation sur 5 ans84.99%
Évolution depuis l'introduction en bourse1,067.25%

Nouvelles et mises à jour récentes

Recent updates

Article d’analyse • Jan 10

We Think Pro-Dex (NASDAQ:PDEX) Can Manage Its Debt With Ease

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Article d’analyse • Nov 14

Even With A 26% Surge, Cautious Investors Are Not Rewarding Pro-Dex, Inc.'s (NASDAQ:PDEX) Performance Completely

Those holding Pro-Dex, Inc. ( NASDAQ:PDEX ) shares would be relieved that the share price has rebounded 26% in the last...
Article d’analyse • Sep 09

Earnings Working Against Pro-Dex, Inc.'s (NASDAQ:PDEX) Share Price Following 26% Dive

Pro-Dex, Inc. ( NASDAQ:PDEX ) shares have had a horrible month, losing 26% after a relatively good period beforehand...
Article d’analyse • Sep 06

We Think Pro-Dex (NASDAQ:PDEX) Can Stay On Top Of Its Debt

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Article d’analyse • Aug 13

With EPS Growth And More, Pro-Dex (NASDAQ:PDEX) Makes An Interesting Case

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Article d’analyse • May 31

Pro-Dex, Inc.'s (NASDAQ:PDEX) 39% Dip In Price Shows Sentiment Is Matching Earnings

The Pro-Dex, Inc. ( NASDAQ:PDEX ) share price has softened a substantial 39% over the previous 30 days, handing back...
Article d’analyse • May 04

Here's Why Pro-Dex (NASDAQ:PDEX) Has Caught The Eye Of Investors

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Article d’analyse • Apr 16

Pro-Dex, Inc.'s (NASDAQ:PDEX) P/E Is Still On The Mark Following 29% Share Price Bounce

Pro-Dex, Inc. ( NASDAQ:PDEX ) shares have continued their recent momentum with a 29% gain in the last month alone. The...
Article d’analyse • Apr 03

Pro-Dex (NASDAQ:PDEX) Looks To Prolong Its Impressive Returns

What are the early trends we should look for to identify a stock that could multiply in value over the long term...
Article d’analyse • Feb 24

This Analyst Just Made A Decent Upgrade To Their Pro-Dex, Inc. (NASDAQ:PDEX) Earnings Forecasts

Pro-Dex, Inc. ( NASDAQ:PDEX ) shareholders will have a reason to smile today, with the covering analyst making...
Article d’analyse • Feb 05

Some Pro-Dex, Inc. (NASDAQ:PDEX) Shareholders Look For Exit As Shares Take 27% Pounding

Pro-Dex, Inc. ( NASDAQ:PDEX ) shares have had a horrible month, losing 27% after a relatively good period beforehand...
Article d’analyse • Nov 13

This Analyst Just Made A Massive Upgrade To Their Pro-Dex, Inc. (NASDAQ:PDEX) Earnings Forecasts

Pro-Dex, Inc. ( NASDAQ:PDEX ) shareholders will have a reason to smile today, with the covering analyst making...
Article d’analyse • Nov 05

Pro-Dex, Inc. (NASDAQ:PDEX) Stock Rockets 31% As Investors Are Less Pessimistic Than Expected

Despite an already strong run, Pro-Dex, Inc. ( NASDAQ:PDEX ) shares have been powering on, with a gain of 31% in the...
Article d’analyse • Sep 10

Pro-Dex, Inc.'s (NASDAQ:PDEX) P/E Is Still On The Mark Following 37% Share Price Bounce

The Pro-Dex, Inc. ( NASDAQ:PDEX ) share price has done very well over the last month, posting an excellent gain of 37...
Article d’analyse • Jul 18

The Returns On Capital At Pro-Dex (NASDAQ:PDEX) Don't Inspire Confidence

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Ideally, a business...
Article d’analyse • Feb 16

Investors Can Find Comfort In Pro-Dex's (NASDAQ:PDEX) Earnings Quality

Pro-Dex, Inc.'s ( NASDAQ:PDEX ) earnings announcement last week didn't impress shareholders. While the headline numbers...
Article d’analyse • Feb 14

Here's Why Pro-Dex (NASDAQ:PDEX) Can Manage Its Debt Responsibly

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Article d’analyse • Jan 24

Pro-Dex, Inc.'s (NASDAQ:PDEX) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Pro-Dex, Inc. ( NASDAQ:PDEX ) shareholders have had their patience rewarded with a 26% share price jump in the last...
Article d’analyse • May 20

Pro-Dex (NASDAQ:PDEX) Has A Pretty Healthy Balance Sheet

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Article d’analyse • Oct 05

Pro-Dex (NASDAQ:PDEX) Could Be Struggling To Allocate Capital

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Seeking Alpha • Sep 26

Pro-Dex: Growth Trends In Earnings, Return On Investment Contracting

Summary Following its FY22 numbers Pro-Dex continues to realize a softening set of fundamentals. Growth trends in earnings and return on investment have been contracting on a sequential basis throughout the pandemic. Valuations do not support substantial upside, in my estimation. Net-net I've rated PDEX a hold with a $14.30 price target which reflects 10.5x FY23 earnings estimates. Investment summary The market has been doing all of the talking in in FY22 and in doing so has been doing the heavy lifting for us stock pickers. If you consider the market to be somewhat efficient [we do], and are an avid believer in data-driven fundamentals [again], then you'd have to agree that there's been a sigh of relief with the unwinding of the high-beta, growth trade of FY20'–21'. Investors are finally paying attention to fundamentals again, and the resulting factor rotation into defensives, quality and the likes has seen a rapid drawdown in wildly valued companies. Whilst we can think tech and private equity all we want, of equal substance here is the health care and medical technology ("medtech") sector[s]. Of no fault of its own, the medical and surgical equipment domains caught a strong bid across FY21 even with weakening fundamentals across the time period. Case in point is Pro-Dex, Inc (PDEX) whereby investors rewarded narrative versus numbers during the pandemic. The stock trades around 52-week lows and continues to push lower as the market continues to deal with the overvalued pockets that still linger around to this day. I've found the company's fundamentals have been weakening over the past 2 years and that investors may have been correct in re-rating the stock to its lowest average market cap in around 2-years. Net-net, I rate PDEX a hold, and note valuations are supportive of this view along with the above-mentioned points. For a quick overview, the company designs and manufactures surgical devices used in the thoracic, orthopaedic and craniomaxillofacial ("CMF") markets. It manufactures multifunctional surgical drivers and shavers that use the company's 'adaptive torque-limiting technology' and other IP that is sells to distributors. It books revenue on this basis and here, I've gone a little deeper into the company's numbers to understand how it is spending its money, and what value it is creating on this. PDEX FY22 results illustrate market headwinds The company came in with a weak set of results in FY22 compared to the previous 12 months. Net sales of $42.04 million ("mm") came in on a 10.5% YoY growth schedule whereas the cost of this turnover increased 18.2% YoY to $28.9mm. This led gross margin to compress by ~440bps YoY to 31.2%. Moving down the P&L, and OPEX came in 11% lower than FY21 due to reduced selling expenditure and a 32% YoY reduction to R&D spend. As such, PDEX recognized some upward mobility in operating income to $5.1mm and brought this down to a net income of $3.855mm, well behind FY21's $5.82mm in net profit. However, I'd note FY21 included $2.47mm in 'other' income that wasn't booked in FY22, and removing this from the equation earnings actually stretched up by 15% YoY. Meanwhile, it printed a loss of $2.52mm in FCF for the year. PDEX's FCF bridge for the 12 months is seen in Exhibit 1. Medical device sales make up 81% of turnover for PDEX, made up of revenue from orthopaedic, CMF and thoracic segments. Orthopaedic sales lifted 21.9% YoY and printed $21.87mm and made up 64% of total medical device turnover. Exhibit 1. Note: All figures in $mm. (Data: HB Insights, PDEX SEC Filings) PDEX fair view of fundamentals Deeper analysis on the company's FY22 numbers illustrate that concentration risk from customer's increased YoY. To illustrate, PDEX's top 3 customers attributed 88% of sales compared to 91% the year prior. However, there was 1 customer that accounted for ~66% of turnover, with the second largest customer generating 14%. Compared to FY21 the breakdown was 58% and 27% respectively. PDEX also had a backlog of $16.5mm at the end of FY22, and this was up 70.1% YoY and management said this is backed by firm purchase orders. Meanwhile, distribution of gross–operating profit has been lumpy on a sequential basis from FY20 to date, as seen in Exhibit 2. Similar trends are observed in free cash flow ("FCF") and FCF yield. Whereas PDEX recognized solid growth numbers from FY16–FY19 on a quarterly basis, this pattern has become less consistent throughout the pandemic, such that operating profit narrowed by CAGR 25.7% over this time. On this, TTM FCF yields have continued their descent from FY17, and PDEX realized a cumulative FCF loss of $10.75mm across the course of the pandemic. Exhibit 2. Reversal of [profit] growth trends from top to bottom line throughout pandemic. FCF yields continued descent – question becomes if there is the return on capital/investment to measure this as a positive result. Cumulative $10.75mm FCF loss across course of pandemic [quarterly]. Note: All figures in $mm or [%]. Free cash flow calculated as [NOPAT - investments]. FCF yield as a function of enterprise value on trailing twelve month basis. All calculations made from GAAP earnings with no reconciliations. (Image: HB Insights. Data: HB Insights, PDEX SEC Filings. ) The question then becomes if the FCF 'spend' has been realized back in the company's return on investment. In particular, I wanted to examine how much NOPAT the company generated from the previous period's invested capital. I've measured this as return on invested capital ("ROIC") and return on assets ("ROA") on a TTM basis. As seen in Exhibit 3, there is no divergence in the PDEX's return on investment to the FCF yield from FY20 to date. Both have been contracting in this time. Ideally, we'd see some bifurcation of ROIC and ROA to the upside, indicating that FCF was well 'spent' over the testing period, however this isn't the case in my estimation. From what we've observed so far in FY22, names that have been growing return on investment over the past 5 years have withstood the downside this YTD. Hence, this is an important factor in the PDEX investment debate. Exhibit 4. Positive correlation of PDEX's return on investment [ROIC, ROA], to FCF yield.
Article d’analyse • Sep 20

When Should You Buy Pro-Dex, Inc. (NASDAQ:PDEX)?

While Pro-Dex, Inc. ( NASDAQ:PDEX ) might not be the most widely known stock at the moment, it saw a decent share price...
Seeking Alpha • Aug 25

Pro-Dex GAAP EPS of $0.38, revenue of $12.61M

Pro-Dex press release (NASDAQ:PDEX): Q4 GAAP EPS of $0.38. Revenue of $12.61M (+33.6% Y/Y).
Article d’analyse • May 10

Is Now The Time To Look At Buying Pro-Dex, Inc. (NASDAQ:PDEX)?

Pro-Dex, Inc. ( NASDAQ:PDEX ), is not the largest company out there, but it received a lot of attention from a...
Article d’analyse • Apr 21

Is Pro-Dex (NASDAQ:PDEX) Using Too Much Debt?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Article d’analyse • Mar 14

Pro-Dex (NASDAQ:PDEX) Is Doing The Right Things To Multiply Its Share Price

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
Article d’analyse • Feb 09

Is Pro-Dex, Inc. (NASDAQ:PDEX) Potentially Undervalued?

Pro-Dex, Inc. ( NASDAQ:PDEX ), might not be a large cap stock, but it saw significant share price movement during...
Article d’analyse • Nov 17

We Think Pro-Dex (NASDAQ:PDEX) Is Taking Some Risk With Its Debt

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Rendement pour les actionnaires

PDEXUS Medical EquipmentUS Marché
7D10.5%4.0%-0.3%
1Y43.0%-18.6%26.7%

Rendement vs Industrie: PDEX a dépassé le secteur US Medical Equipment qui a rapporté -18.6 % au cours de l'année écoulée.

Rendement vs marché: PDEX a dépassé le marché US qui a rapporté 26.7 % au cours de l'année écoulée.

Volatilité des prix

Is PDEX's price volatile compared to industry and market?
PDEX volatility
PDEX Average Weekly Movement6.7%
Medical Equipment Industry Average Movement8.6%
Market Average Movement7.2%
10% most volatile stocks in US Market16.2%
10% least volatile stocks in US Market3.2%

Cours de l'action stable: PDEX n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.

Volatilité au fil du temps: La volatilité hebdomadaire de PDEX ( 7% ) est restée stable au cours de l'année écoulée.

À propos de l'entreprise

FondéeSalariésPDGSite web
1978180Rick Van Kirkwww.pro-dex.com

Pro-Dex, Inc. conçoit, développe, fabrique et vend des instruments chirurgicaux motorisés pour les fabricants d'équipements médicaux dans le monde entier. Elle propose des moteurs chirurgicaux et des rasoirs autoclavables, alimentés par batterie ou électriques, et multifonctions, qui sont principalement utilisés sur les marchés orthopédique, thoracique et craniomaxillofacial. L'entreprise fournit également des services de conseil en ingénierie, en qualité et en réglementation, et fabrique et vend des moteurs pneumatiques rotatifs à diverses industries.

Pro-Dex, Inc. Résumé des fondamentaux

Comment les bénéfices et les revenus de Pro-Dex se comparent-ils à sa capitalisation boursière ?
PDEX statistiques fondamentales
Capitalisation boursièreUS$194.06m
Bénéfices(TTM)US$12.00m
Recettes(TTM)US$74.64m
16.9x
Ratio P/E
2.7x
Ratio P/S

Le site PDEX est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
PDEX compte de résultat (TTM)
RecettesUS$74.64m
Coût des recettesUS$53.90m
Marge bruteUS$20.74m
Autres dépensesUS$8.73m
Les revenusUS$12.00m

Derniers bénéfices déclarés

Mar 31, 2026

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)3.76
Marge brute27.78%
Marge bénéficiaire nette16.08%
Ratio dettes/capitaux propres40.9%

Quelles ont été les performances à long terme de PDEX?

Voir les performances historiques et les comparaisons

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/05/20 07:27
Cours de l'action en fin de journée2026/05/20 00:00
Les revenus2026/03/31
Revenus annuels2025/06/30

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Pro-Dex, Inc. est couverte par 1 analystes. 1 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Edward WooAscendiant Capital Markets LLC